Article info
PDFResearch ethics
“Hello, hello—it’s English I speak!”: a qualitative exploration of patients’ understanding of the science of clinical trials
- Correspondence to: Martine Stead Deputy Director, Institute for Social Marketing, University of Stirling and the Open University, Stirling FK9 4LA, UK; martine.steadstir.ac.uk
Citation
“Hello, hello—it’s English I speak!”: a qualitative exploration of patients’ understanding of the science of clinical trials
Publication history
- Received October 28, 2004
- Accepted February 19, 2005
- First published November 3, 2005.
Online issue publication
April 27, 2016
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Copyright 2005 by the Journal of Medical Ethics
Other content recommended for you
- Clinical research on COVID-19: perceptions and barriers to participation in The Gambia
- Are patients with amyotrophic lateral sclerosis at risk of a therapeutic misconception?
- Is it ethical to keep interim findings of randomised controlled trials confidential?
- Informed consent in clinical research in France: assessment and factors associated with therapeutic misconception
- Should desperate volunteers be included in randomised controlled trials?
- Randomised placebo-controlled trials of surgery: ethical analysis and guidelines
- Simplified consent in cluster randomised trials: the new EU Clinical Trials Regulation does not provide sufficient guidance
- Understanding, interests and informed consent: a reply to Sreenivasan
- The ethics of randomised controlled trials from the perspectives of patients, the public, and healthcare professionals
- Exenatide once weekly over 2 years as a potential disease-modifying treatment for Parkinson’s disease: protocol for a multicentre, randomised, double blind, parallel group, placebo controlled, phase 3 trial: The ‘Exenatide-PD3’ study